Fate Therapeutics, Inc. (FATE) Stock Price, Financial Report, & Fundamental AnalysisNASDAQ:FATE
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors.
Fate Therapeutics, Inc. Fundamental Analysis
FATE has had growing revenue for the last 5 years
Price to Book (PBV) Ratio
Overvalued price-to-book. FATE stock price is overvalued by more than 1x the price-to-book value.
Debt-Equity Ratio (DER)
FATE equity is higher than it's debt.
FATE has positive revenue for last 5 years
Small market capitalization. Market capitalization is less than 2bn USD
Net Income Growth
FATE has never had growing net income.
FATE never has positive net income for 2 years.
FATE has low dividend yield (0%).
Return of Assets
FATE has low return of asset (-39.23%).
Return of Equity
FATE has low return of equity (-48.78%).
Return of Invested Capital
FATE has low ROIC.
Fate Therapeutics, Inc. Financials
Financial statements are written records that convey the business activities and the financial performance of a company. Financial statements include the balance sheet, income statement, and statement of cash flow.
Also known as the profit and loss (P&L) statement or the statement of revenue and expense, the income statement primarily focuses on the company’s revenue and expenses during a particular period.
- 55,846,000 USD
- 272,840,000 USD
- Net Income
- -212,151,000 USD
- Profit Margin
A cash flow statement is a financial statement that provides aggregate data regarding all cash inflows a company receives from its ongoing operations and external investment sources. It also includes all cash outflows that pay for business activities and investments during a given period.
- Free Cash Flow
- -213,574,000 USD
Liquidity & Solvency
Solvency refers to an company's capacity to meet its long-term financial commitments. Liquidity refers to an company's ability to pay short-term obligations. The term also refers to a company's capability to sell assets quickly to raise cash.
Short Term Liabilities
Long Term Liabilities
|Dividend Payout Ratio (DPR)||0%|
|Dividend Payout Ratio (DPR)||0%|
|Dividend per Share||0,00 USD|
|Price to Earning (PER)||-4x|
|Price to Earning-Growth (PEG)||0x|
|Price to Book Value (PBV)||0x|
|Debt-Equity Ratio (DER)||44.66%|
|Net Profit Margin (NPM)||-425.98%|
|Return of Assets (ROA)||-39.23%|
|Return of Equity (ROE)||-48.78%|
|Return on Capital Employed (ROCE)||-48.55%|
|Days of Sales Outstanding (DSO)||54.07|
|Days of Inventory Outstanding (DIO)||0|
|Days Payable Outstanding (DPO)||0|
|Operating Cycle (OC)||0|
|Cash Conversion Cycle (CCC)||0|
Fate Therapeutics, Inc. Executives
- CEO Name
- Mr. John Wolchko
Fate Therapeutics, Inc. Profile
About Fate Therapeutics, Inc.
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
- Company name
- Fate Therapeutics, Inc.
- NASDAQ Global Market
3535 General Atomics Ct Ste 200